Fortimedix Surgical

Year of investment: 2016

Fortimedix Surgical is a fast growing medical device company, aiming to challenge the status quo in minimally invasive surgery by creating novel devices that capture the claimed benefits of single-port surgery. The company is headquartered in Nuth, The Netherlands, and has a US subsidiary in San Diego, CA. With a strong history as a global market leader in contract stent manufacturing, Fortimedix has been a trusted partner in the medical device industry for over 15 years. Fortimedix Surgical is committed to driving the evolution of minimally invasive surgery through smart innovation across surgical specialties to improve the quality of life of patients throughout the world.

Enzypep

Year of investment: 2014

Enzypep developed a breakthrough technology for the synthesis of peptides using enzymes. The Enzypep technology is expected to become the state-of-the-art in design and preparation of complex peptides. Compared with standard synthesis it results in pharmaceutical products with a much higher purity, at a much lower cost and in a sustainable, environmentally-friendly manner.

Ioniqa Technologies

Year of investment: 2015

Ioniqa Technologies has a patented technology that uses magnetic colloidal systems with nanoparticles to break down PET into a re-usable monomer. The unique feature of this technology is its ability to remove pigmentation which opens up the range of available PET feedstock that can be recycled economically.

Black Bear Carbon

Year of investment: 2015

Black Bear Carbon converts used tires into prime grade carbon black and green energy via a proprietary pyrolysis process. Black Bear is an example of the circular economy, addressing an important societal need to re-use resources and reduce CO₂ emission.

Cristal Therapeutics

Year of investment: 2014

Cristal Therapeutics (formerly known as Cristal Delivery) is a pharmaceutical company developing a new class of nanomedicine based on its proprietary polymeric technologies, registered as CriPec®. Cristal Therapeutic’s mission is optimize the therapeutic performance of drugs and thereby improve patient care.

QC Polymers

Year of investment: 2014

QC Polymers operates a polymer recycling plant with a nameplate capacity of 50,000 tons/year in Sittard-Geleen to produce polyethylene and polypropylene compounds from post-consumer and post-industrial waste. Typical applications are bottles, crates, pipes and automotive parts.